肾移植后新发糖尿病:依据术前病毒血清学选择免疫抑制方案能否改变风险?
该研究分析成人肾移植受者中,术前病毒血清学与免疫抑制方案和新发糖尿病(NODAT)风险的关联。HCV+或CMV+血清学是NODAT危险因素,而HBc+或EBV+不是。无论HCV或CMV血清学状态如何,与参考方案Tac+MPA相比,CSA+MPA的NODAT风险更低,SRL+CSA或SRL+MPA风险相似;在HCV-或CMV+受者中,SRL+Tac风险更高。依据HCV或CMV血清学调整免疫抑制方案可能改变NODAT风险。
要点
- HCV+或CMV+血清学与肾移植后NODAT风险升高相关。
- 与Tac+MPA相比,CSA+MPA的NODAT风险更低,且不受HCV或CMV血清学影响。
- 在HCV-或CMV+受者中,SRL+Tac方案NODAT风险高于Tac+MPA。
核心结论
- 依据HCV或CMV血清学调整免疫抑制方案可能改变肾移植受者NODAT风险。
研究设计与样本
- 回顾性队列研究,纳入1995年1月至2015年9月97 644例成人肾移植受者,采用Cox回归分析移植后第一年NODAT风险。
主要发现
- HCV+血清学与NODAT风险升高相关(HR 1.50,95%CI 1.31-1.68)。
- CMV+血清学与NODAT风险升高相关(HR 1.12,95%CI 1.06-1.19)。
- HBc+血清学与NODAT风险无显著关联(HR 1.04,95%CI 0.95-1.15)。
- EBV+血清学与NODAT风险无显著关联(HR 1.06,95%CI 0.97-1.15)。
- 在HCV-或CMV+受者中,SRL+Tac方案NODAT风险高于Tac+MPA(HCV-:HR 1.43,95%CI 1.17-1.74;CMV+:HR 1.44,95%CI 1.14-1.81)。
关键数值与推荐
- 与参考方案Tac+MPA相比,CSA+MPA的NODAT风险在HCV-受者中HR 0.74(95%CI 0.65-0.85),HCV+受者中HR 0.47(95%CI 0.28-0.78)。
- 与参考方案Tac+MPA相比,CSA+MPA的NODAT风险在CMV-受者中HR 0.68(95%CI 0.54-0.86),CMV+受者中HR 0.73(95%CI 0.63-0.85)。
- SRL+CSA或SRL+MPA方案与参考方案Tac+MPA相比,NODAT风险相似。
临床怎么用
- 对于HCV+或CMV+的肾移植受者,选择CSA+MPA方案可能降低NODAT风险。
- 在HCV-或CMV+受者中,应谨慎使用SRL+Tac方案以降低NODAT风险。
局限性
- 本研究为回顾性分析,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to analyze adult kidney transplant recipients (KTRs) for the risk of new-onset diabetes after transplantation (NODAT) associated with viral serologies and immunosuppression regimens [tacrolimus (Tac) + mycophenolate (MPA), cyclosporine (CSA) + MPA, sirolimus (SRL) + MPA, SRL + CSA or SRL +Tac]. METHODS: Cox regression models were used to examine the risk of NODAT in the first posttransplant year associated with: (i) CSA + MPA, SRL + MPA, SRL + MPA or SRL + Tac versus reference, Tac + MPA; (ii) pretransplant viral serology [+ or -; hepatitis B core (HBc), hepatitis C (HCV), cytomegalovirus (CMV) or Epstein Barr Virus (EBV)]; and (iii) interactions between immunosuppression regimens and the viral serology found significant in the main analysis. RESULTS: Adult KTRs (n = 97 644) from January 1995 through September 2015 were studied. HCV+ [hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.31-1.68] or CMV+ (HR 1.12, 95% CI 1.06-1.19) serology was a risk factor and HBc+ (HR 1.04, 95% CI 0.95-1.15) or EBV+ (HR 1.06, 95% CI 0.97-1.15) serology was not a risk factor for NODAT. Regardless of associated HCV or CMV serology, risk of NODAT relative to the reference regimen (Tac + MPA) was lower with CSA + MPA [HCV-: HR 0.74, 95% CI 0.65-0.85; HCV+: HR 0.47, 95% CI 0.28-0.78; CMV-: CSA + MPA HR 0.68, 95% CI 0.54-0.86; CMV+: (CSA + MPA) HR 0.73, 95% CI 0.63-0.85] and similar with SRL + CSA or SRL + MPA. In KTRs with HCV- or CMV+ serology, SRL + Tac was associated with a higher risk of NODAT relative to reference [HCV- (HR 1.43, 95% CI 1.17-1.74) and CMV+ (HR 1.44, 95% CI 1.14-1.81), respectively]. The risk for NODAT-free graft loss was lower with Tac + MPA than the other regimens. CONCLUSIONS: Tailoring immunosuppression regimen based on HCV or CMV serology may modify the risk of developing NODAT in KTRs.
引用
- Santos AH, Chen C, Casey MJ, et al. New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology? Nephrol Dial Transplant. 2018. PMID: 29045704. doi:10.1093/ndt/gfx281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。